11/17/2015 - 12:58pm

Ajanta is launching its fifth generic product in the U.S. that has received Food and Drug administration approval. 

11/17/2015 - 9:16am

Tagrisso is an EGFR-tyrosine kinase inhibitor, a targeted cancer therapy, designed to inhibit both the activating, sensitizing mutations, and T790M, the genetic mutation responsible for EGFR-TKI treatment resistance in up to approximately two-thirds of cases of EGFRm advanced NSCLC. 

11/16/2015 - 2:56pm

The drug is meant to be used on-demand to control bleeding episodes and as a way to reduce their frequency.

11/16/2015 - 1:09pm

For those patients receiving 90-day supplies of chronic medications, their MPR was 1.4 points higher than the control group as a result of using CVS/pharmacy's ReadyFill program. 

11/16/2015 - 11:38am

Mylan has launched two generics — one for diabetes and another for HIV — following final Food and Drug Administration approval. 

11/13/2015 - 3:50pm

The New York Times is reporting that Manhatta-based pharmacy Irmat, which dispenses products nationwide through the mail is suing UnitedHealth Group’s PBM OptumRx, which plans to drop Irmat at the end of the year. The move follows controversy over Valeant Pharmaceuticals’ involvement with specialty mail-order pharmacy Philidor, which was dropped by Express Scripts, Optum and CVS Caremark in October. (New York Times)

11/13/2015 - 3:18pm
The drug was granted Fast Track, Breakthrough, Priority Review and Accelerated Approval status by the FDA and has shown an objective response rate of 59% with a median duration of about 12.4 months. 
11/13/2015 - 1:19pm

AtlanticLIVE’s event, “The Diabetes Divide,” addressed an issue that affects an estimated 415 million people worldwide. 

11/13/2015 - 10:09am

Perrigo’s shareholders did not tender a majority of the company’s shares to Mylan by 8 a.m. EST Friday, effectively ending Mylan’s acquisition attempt.